Video

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Laurie H. Sehn, MD, MPH, clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, discusses bioengineered monoclonal antibodies and their promising future in treating patients with lymphoma. At the 53rd Annual Meeting of the American Society of Hematology, held in San Diego, Sehn presented phase II data on GA101, a monoclonal antibody that targets CD20, and how it might perform even better than rituximab, a practice-changing therapy for patients with non-Hodgkin lymphoma.

Related Videos
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.